{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT03827876",
            "orgStudyIdInfo": {
                "id": "PTC04"
            },
            "organization": {
                "fullName": "Psoriasis Treatment Center of Central New Jersey",
                "class": "OTHER"
            },
            "briefTitle": "Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis",
            "officialTitle": "An Open-Label Study Evaluating Enstilar\u00ae (Calcipotriene and Betamethasone Dipropionate) Foam, 0.005%/0.064% QD in Psoriasis Patients Being Treated With Etanercept or Adalimumab",
            "therapeuticArea": [
                "Dermatology"
            ],
            "study": "enstilar-in-combination-with-enbrel-or-humira-for-plaque-psoriasis"
        },
        "statusModule": {
            "statusVerifiedDate": "2019-01",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2019-01-16",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2019-09-15",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2019-12-15",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2019-01-29",
            "studyFirstSubmitQcDate": "2019-01-31",
            "studyFirstPostDateStruct": {
                "date": "2019-02-04",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2019-01-31",
            "lastUpdatePostDateStruct": {
                "date": "2019-02-04",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Psoriasis Treatment Center of Central New Jersey",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "LEO Pharma",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "4 weeks of adjunctive therapy of Enstilar\u00ae QD followed by 12 weeks QOD to patients with 2-10% BSA who are receiving etanercept or adalimumab for at least 24 weeks",
            "detailedDescription": "30 subjects treated with etanercept or adalimumab for at least 24 weeks with a body surface area 2-10% and physician global assessment greater than or equal to 2 will receive Enstilar\u00ae once daily for 4 weeks followed by QOD for 12 weeks."
        },
        "conditionsModule": {
            "conditions": [
                "Psoriasis"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE4"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "interventionModelDescription": "open label",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 30,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Open Label Enstilar",
                    "type": "EXPERIMENTAL",
                    "description": "once daily for 4 weeks followed by QOD for 12 weeks for patients receiving Enbrel or Humira",
                    "interventionNames": [
                        "Drug: Enstilar 0.005%-0.064% Topical Foam"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Enstilar 0.005%-0.064% Topical Foam",
                    "description": "Enstilar 0.005%-0.064% Topical Foam applied once daily for 4 weeks followed by QOD for 12 weeks for patients receiving Enbrel or Humira",
                    "armGroupLabels": [
                        "Open Label Enstilar"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "PGA x BSA improvement",
                    "description": "body surface area multiplied by physician global assessment",
                    "timeFrame": "16 weeks"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "BSA improvement",
                    "description": "body surface area improvement",
                    "timeFrame": "16 weeks"
                },
                {
                    "measure": "Dermatology Life Quality Index improvement",
                    "description": "patient reported outcome improvements of DLQI (Dermatology Life Quality Index). Calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired. The DLQI can also be expressed as a percentage of the maximum possible score of 30.",
                    "timeFrame": "16 weeks"
                },
                {
                    "measure": "Itch Numerical Rating Scale",
                    "description": "Patient reported itch scale from 0 (no itch) to 10 (worst imaginable itch).",
                    "timeFrame": "16 weeks"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Male or female adult \u2265 18 years of age;\n* Diagnosis of chronic plaque-type\n* Patient with 2-10% BSA\n* Physician Global Assessment of 2 or greater\n* Patient has been treated with etanercept or adalimumab for a minimum of 24 weeks\n\nExclusion Criteria:\n\n* \u02c22 or \\>10% BSA\n* PGA \\<2\n* Patient not receiving etanercept or adalimumab, or receiving etanercept or adalimumab \\<24weeks",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Jerry Bagel, MD",
                    "role": "CONTACT",
                    "phone": "6094434500",
                    "email": "dreamacres1@aol.com"
                },
                {
                    "name": "Elise Nelson",
                    "role": "CONTACT",
                    "phone": "6094434500",
                    "email": "enelson@windsordermatology.com"
                }
            ],
            "locations": [
                {
                    "facility": "Psoriasis Treatment Center of Central New Jersey",
                    "status": "RECRUITING",
                    "city": "East Windsor",
                    "state": "New Jersey",
                    "zip": "08520",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Elise Nelson",
                            "role": "CONTACT",
                            "phone": "609-443-4500",
                            "phoneExt": "1402",
                            "email": "enelson@windsordermatology.com"
                        },
                        {
                            "name": "Jerry Bagel, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        },
                        {
                            "name": "Brian Keegan, MD, PhD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "David Nieves, MD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Alexa Hetzel, PA-C",
                            "role": "SUB_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.268,
                        "lon": -74.54043
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30",
            "submissionTracking": {
                "estimatedResultsFirstSubmitDate": "2024-03-14",
                "submissionInfos": [
                    {
                        "releaseDate": "2024-03-14",
                        "resetDate": "2024-04-09",
                        "mcpReleaseN": 1
                    }
                ]
            }
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000011565",
                    "term": "Psoriasis"
                }
            ],
            "ancestors": [
                {
                    "id": "D000017444",
                    "term": "Skin Diseases, Papulosquamous"
                },
                {
                    "id": "D000012871",
                    "term": "Skin Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M14422",
                    "name": "Psoriasis",
                    "asFound": "Psoriasis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M15674",
                    "name": "Skin Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M19713",
                    "name": "Skin Diseases, Papulosquamous",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000002117",
                    "term": "Calcitriol"
                },
                {
                    "id": "D000001623",
                    "term": "Betamethasone"
                },
                {
                    "id": "C000011175",
                    "term": "Betamethasone-17,21-dipropionate"
                },
                {
                    "id": "C000055085",
                    "term": "Calcipotriene"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000893",
                    "term": "Anti-Inflammatory Agents"
                },
                {
                    "id": "D000005938",
                    "term": "Glucocorticoids"
                },
                {
                    "id": "D000006728",
                    "term": "Hormones"
                },
                {
                    "id": "D000006730",
                    "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000018927",
                    "term": "Anti-Asthmatic Agents"
                },
                {
                    "id": "D000019141",
                    "term": "Respiratory System Agents"
                },
                {
                    "id": "D000077264",
                    "term": "Calcium-Regulating Hormones and Agents"
                },
                {
                    "id": "D000002120",
                    "term": "Calcium Channel Agonists"
                },
                {
                    "id": "D000049990",
                    "term": "Membrane Transport Modulators"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000014662",
                    "term": "Vasoconstrictor Agents"
                },
                {
                    "id": "D000014815",
                    "term": "Vitamins"
                },
                {
                    "id": "D000018977",
                    "term": "Micronutrients"
                },
                {
                    "id": "D000050071",
                    "term": "Bone Density Conservation Agents"
                },
                {
                    "id": "D000003879",
                    "term": "Dermatologic Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M326",
                    "name": "Adalimumab",
                    "relevance": "LOW"
                },
                {
                    "id": "M4909",
                    "name": "Betamethasone",
                    "asFound": "Zicronapine",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4910",
                    "name": "Betamethasone Valerate",
                    "relevance": "LOW"
                },
                {
                    "id": "M229285",
                    "name": "Betamethasone-17,21-dipropionate",
                    "asFound": "Zicronapine",
                    "relevance": "HIGH"
                },
                {
                    "id": "M259190",
                    "name": "Betamethasone benzoate",
                    "relevance": "LOW"
                },
                {
                    "id": "M248787",
                    "name": "Betamethasone sodium phosphate",
                    "relevance": "LOW"
                },
                {
                    "id": "M350710",
                    "name": "Calcipotriene",
                    "asFound": "Zicronapine",
                    "relevance": "HIGH"
                },
                {
                    "id": "M311",
                    "name": "Etanercept",
                    "relevance": "LOW"
                },
                {
                    "id": "M5380",
                    "name": "Calcitriol",
                    "asFound": "Zicronapine",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4217",
                    "name": "Anti-Inflammatory Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M9047",
                    "name": "Glucocorticoids",
                    "relevance": "LOW"
                },
                {
                    "id": "M9789",
                    "name": "Hormones",
                    "relevance": "LOW"
                },
                {
                    "id": "M9788",
                    "name": "Hormone Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M20963",
                    "name": "Anti-Asthmatic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M21137",
                    "name": "Respiratory System Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M5381",
                    "name": "Calcium",
                    "relevance": "LOW"
                },
                {
                    "id": "M5398",
                    "name": "Calcium, Dietary",
                    "relevance": "LOW"
                },
                {
                    "id": "M17409",
                    "name": "Vasoconstrictor Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M17558",
                    "name": "Vitamins",
                    "relevance": "LOW"
                },
                {
                    "id": "M21009",
                    "name": "Micronutrients",
                    "relevance": "LOW"
                },
                {
                    "id": "M16885",
                    "name": "Trace Elements",
                    "relevance": "LOW"
                },
                {
                    "id": "M7074",
                    "name": "Dermatologic Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Infl",
                    "name": "Anti-Inflammatory Agents"
                },
                {
                    "abbrev": "ARhu",
                    "name": "Antirheumatic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Resp",
                    "name": "Respiratory System Agents"
                },
                {
                    "abbrev": "Derm",
                    "name": "Dermatologic Agents"
                },
                {
                    "abbrev": "Analg",
                    "name": "Analgesics"
                },
                {
                    "abbrev": "Gast",
                    "name": "Gastrointestinal Agents"
                },
                {
                    "abbrev": "BDCA",
                    "name": "Bone Density Conservation Agents"
                },
                {
                    "abbrev": "Micro",
                    "name": "Micronutrients"
                },
                {
                    "abbrev": "VaCoAg",
                    "name": "Vasoconstrictor Agents"
                }
            ]
        }
    },
    "hasResults": false
}